Company profile
OCULIS HOLDING AG
NASDAQ:OCSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LICAMINLIMAB | phase2_3 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07548632 | phase2_3 | recruiting | 2026-04-16 | 2026-12-01 | Oculis | A Clinical Study Evaluating Licaminlimab for Dry Eye Disease |
| NCT05147233 | phase3 | completed | 2022-06-24 | 2023-06-22 | Oculis | A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery |
| NCT06128369 | phase3 | terminated | 2023-12-18 | 2024-05-02 | Oculis | A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery |
| NCT05066997 | phase2_3 | completed | 2021-10-19 | 2026-04-10 | Oculis | A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) |
| NCT06172257 | phase3 | completed | 2024-03-15 | 2026-04-02 | Oculis | A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) |
FDA applications (0)
No records yet.